CARISMA THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | -2.65% |
|
-9.26% | -49.83% |
| 09/05 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02/05 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 16.07M 1.34B | Sales 2025 * | 16.2M 1.35B | Capitalization | 62.73M 5.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.93B | Net income 2025 * | -63M -5.26B | EV / Sales 2024 * | 3.9 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.87 x |
| P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-1.31
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.65% | ||
| 1 week | -9.26% | ||
| Current month | -9.82% | ||
| 1 month | -23.04% | ||
| 3 months | -34.96% | ||
| 6 months | -38.62% | ||
| Current year | -49.83% |
1 week
1.43
1.66
1 month
1.432.04
Current year
1.433.06
1 year
1.439.77
3 years
1.439.77
5 years
1.439.77
10 years
1.439.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 01/16/01 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 01/18/01 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 01/18/01 |
Sanford Zweifach
CHM | Chairman | 68 | 01/21/01 |
| Director/Board Member | 66 | 01/22/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | +3.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/24/11 | 1.47 | -2.65% | 180 166 |
| 09/24/09 | 1.51 | -2.58% | 185,533 |
| 08/24/08 | 1.55 | 0.00% | 132,776 |
| 07/24/07 | 1.55 | -2.82% | 115,877 |
| 06/24/06 | 1.595 | -1.54% | 121,132 |
Delayed Quote Nasdaq, May 11, 2024 at 01:14 am IST
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
13/05/2024
- Citizens JMP Life Sciences Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.51
USD
Average target price
8.4
USD
Spread / Average Target
+456.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.83% | 62.73M | |
| +3.91% | 108B | |
| +11.25% | 104B | |
| +1.28% | 22.33B | |
| -13.01% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -9.96% | 17.64B | |
| +3.79% | 14.05B | |
| +36.44% | 12.51B |
- Stock Market
- Equities
- CARM Stock